Validating posttransplant hepatocellular carcinoma recurrence data in the united network for organ sharing database

Liver Transplantation

Volumn 19, Issue 12, 2013, Pages 1318-1323

  Samoylova, Mariya L ^a   Dodge, Jennifer L ^a   Vittinghoff, Eric ^a   Yao, Francis Y ^a   Roberts, John Paul ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABLATION THERAPY; ADULT; ARTICLE; CANCER RECURRENCE; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HUMAN; LIVER CELL CARCINOMA; LIVER GRAFT; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT;

CARCINOMA, HEPATOCELLULAR; DATABASES, FACTUAL; FEMALE; HUMANS; INCIDENCE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TISSUE AND ORGAN PROCUREMENT; TREATMENT OUTCOME; UNITED STATES;

EID: 84889102306     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23735     Document Type: Article

References (12)

1. Organ Procurement and Transplantation Network. OPTN policy 7.0. Data submission requirements. http://optn.transplant.hrsa.gov/PoliciesandBylaws2/ policies/pdfs/policy-23.pdf. Accessed June 2013.
2. Wald C, Russo MW, Heimbach JK, Hussain HK, Pomfret EA, Bruix J,. New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Radiology 2013; 266: 376-382.
3. Gilmore AS, Helderman JH, Ricci JF, Ryskina KL, Feng S, Kang N, Legorreta AP,. Linking the US transplant registry to administrative claims data: expanding the potential of transplant research. Med Care 2007; 45: 529-536.
4. Gillespie BW, Merion RM, Ortiz-Rios E, Tong L, Shaked A, Brown RS, et al.; for A2ALL Study Group. Database comparison of the Adult-To-Adult Living Donor Liver Transplantation Cohort Study (A2ALL) and the SRTR U.S. Transplant Registry. Am J Transplant 2010; 10: 1621-1633.
5. Olthoff KM, Abecassis MM, Emond JC, Kam I, Merion RM, Gillespie BW, Tong L,; for Adult-to-Adult Living Donor Liver Transplantation Cohort Study Group. Outcomes of adult living donor liver transplantation: comparison of the Adult-to-Adult Living Donor Liver Transplantation Cohort Study and the national experience. Liver Transpl 2011; 17: 789-797.
6. Feng S, Goodrich NP, Bragg-Gresham JL, Dykstra DM, Punch JD, DebRoy MA, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 2006; 6: 783-790.
7. Ioannou GN, Perkins JD, Carithers RL Jr,. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. Gastroenterology 2008; 134: 1342-1351.
8. Freeman RB Jr, Steffick DE, Guidinger MK, Farmer DG, Berg CL, Merion RM,. Liver and intestine transplantation in the United States, 1997-2006. Am J Transplant 2008; 8: 958-976.
9. Berry K, Ioannou GN,. Serum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinoma. Liver Transpl 2013; 19: 634-645.
10. Toso C, Asthana S, Bigam DL, Shapiro AM, Kneteman NM,. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology 2009; 49: 832-838.
11. Merani S, Majno P, Kneteman NM, Berney T, Morel P, Mentha G, Toso C,. The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. J Hepatol 2011; 55: 814-819.
12. Mukamel DB, Glance LG, Dick AW, Osler TM,. Measuring quality for public reporting of health provider quality: making it meaningful to patients. Am J Public Health 2010; 100: 264-269.